
-
Syros Pharmaceuticals OTC Markets OTCPK:SYRS Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors. The company was formerly known as LS22, Inc. and changed its name to Syros Pharmaceuticals, Inc. in August 2012. Syros Pharmaceuticals, Inc. was incorporated in 2011 and is headquartered in Cambridge, Massachusetts.
Location: 35 CambridgePark Drive, Cambridge, MA, 02140, United States | Website: https://www.syros.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
2.777M
Cash
58.28M
Avg Qtr Burn
-25.0M
Short % of Float
3.52%
Insider Ownership
0.76%
Institutional Own.
16.37%
Qtr Updated
09/30/24
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Tamibarotene (SY-1425) (RARα agonist) in combination with venetoclax and azacitidin Details Acute myeloid leukemia, Cancer | Phase 2 Data readout | |
SM-88 Details Bone cancer, Sarcoma | Failed Discontinued | |
SM-88 Details Sarcoma, Bone cancer, Breast cancer | Failed Discontinued | |
Failed Discontinued | ||
Failed Discontinued | ||
Tamibarotene (SY-1425) (RARα agonist) Details Acute myeloid leukemia, Cancer, Myelodysplastic syndrome | Failed Discontinued | |
TYME-19 Details COVID-19 | Failed Discontinued | |
SM-88 Details Prostate cancer, Prostate disease | Failed Discontinued | |
SM-88 Details Pancreatic cancer | Failed Discontinued |